Dehydroevodiamine

• Description:

  Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes[1]. Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells[2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H317

• Target:

  COX; NF-κB; NO Synthase; PGE synthase

• Type:

  Natural Products

• Related Pathways:

  Immunology/Inflammation; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dehydroevodiamine.html

• Purity:

  99.93

• Solubility:

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1N2C(C([N-]C3=C4C=CC=C3)=C4CC2)=[N+](C)C5=C1C=CC=C5

• Molecular Formula:

  C19H15N3O

• Molecular Weight:

  301.34

• Precautions:

  H302, H317

• References & Citations:

  [1]Loh SH, et al. Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes. J Ethnopharmacol. 2014 May 14;153 (3) :753-62.|[2]Noh EJ, et al. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. 2006 Jul 10;79 (7) :695-701. Epub 2006 Mar 6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• Isoform:

  INOS

• CAS Number:

  [67909-49-3]